Hosted on MSN6mon
GSK, Sanofi, CSL said to win $72M U.S. bird flu vaccine contract (update)
Meanwhile, Sanofi (GCVRZ) and GSK (GSK) are expected to receive $23.4M and $10.5M, respectively. In a statement, CSL (OTCQX:CSLLY) said its CSL Seqirus unit has received a $34M government award to ...
pharmaphorum11y
GSK saw Q3 growth, despite bribery scandal in China
In the third quarter, the company saw 4 of its 6 highlighted assets approved, as well as approval for its quadrivalent flu vaccine, FluLaval. GSK also took a massive step forward this quarter as ...
Hosted on MSN11mon
U.S. Could Vaccinate a Fifth of Americans in a Bird Flu Emergency
CSL Seqirus and GSK, under contract with HHS, are testing vaccines targeting a strain of avian influenza closely related to the one circulating in dairy cows. Each company is running trials in ...
FiercePharma2y
Innovating One of the World’s Most Common Vaccines in Era of Consumer Choice
Stefan Merlo, Vice President of Commercial Development at Seqirus, shares thoughts on the recent innovations in influenza vaccine technology.